Previous 10 | Next 10 |
Kinnate Biopharma aims to raise $170 million in an IPO. The firm is developing kinase inhibitor-based treatment candidates for various cancers. KNTE has produced promising results in preclinical studies, but is still extremely high risk; the IPO may be more suited to long-term hol...
Relay Therapeutics (RLAY): Q3 GAAP EPS of -$3.00.Cash, cash equivalents and investments of $713M. Press Release For further details see: Relay Therapeutics reports Q3 results
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third quarter 2020 financial results. ...
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
Relay Therapeutics ([[RLAY]] +7.3%) is up, albeit on below-average volume, in apparent response to a presentation on the company by fundamental shop EcoR1 Capital at the Sohn Conference.The company debuted on July 16 at $20. Shares are currently exchanging hands at $47.13, up 136%.It develops...
Investment Thesis Relay Therapeutics share price performance since IPO (Source: TradingView ) Investors looking to place a bet on the next big biotech trend may want to take a close look at Relay Therapeutics ( RLAY ), a novel drug discovery startup with a strong management team, ac...
Relay Therapeutics (NASDAQ: RLAY ) has dosed the first patient in a first-in-human clinical trial of RLY-4008 enriched for patients with intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors harboring a fibroblast growth factor receptor 2 (FGFR2) alteration. ...
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the first patient has been dosed in a fi...
This is the 3rd article in a 4-part series on Israel-based Evogene Ltd. ( EVGN ). This article will focus on Evogene's 100% owned subsidiary AgPlenus. For more information about Evogene, I invite you to read the first two articles in this 4-part Evogene series which were published on Seeking...
Relay Therapeutics (NASDAQ: RLAY ) : Q2 GAAP EPS of -$6.06 misses by $5.03 . Cash, cash equivalents and investments totaled $312M as of June 30, 2020 $312M Press Release More news on: Relay Therapeutics, Inc., Earnings news and commentary,
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...